The EPS beat is marginal and overshadowed by the non-recurring revenue drop. Focus on Phase 3 enrollment completion in June 2026 and mid-2027 data readout. The strong cash runway reduces near-term dilution risk but ATM sales remain an overhang. Monitor any regulatory milestones regarding zorevunersen.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 8 $32.89entry
- T+1 · 6mo ago −0.76%α −0.99% · $32.64
- T+5 · 6mo ago −4.65%α −6.12% · $31.36
- T+20 · 5mo ago −8.76%α −8.78% · $30.01
- T+60 · 3mo ago −3.71%α −8.55% · $31.67
Price Chart
How similar events traded
Executive Summary
Stoke Therapeutics reported Q1 2026 net loss of $50.0M ($0.79 per share) vs net income of $112.9M in Q1 2025, which included a $150.8M Biogen license fee. Revenue fell to $6.2M from $158.6M. The company highlighted continued Phase 3 EMPEROR enrollment on track for June 2026 completion and a cash position of $411M funding operations into 2028.
Key Financial Metrics
Key Facts
- Net loss $50.0M ($0.79 per share) vs net income $112.9M ($1.90 diluted) in Q1 2025
- Revenue $6.2M down 96% YoY due to $150.8M prior-year Biogen IP license
- Cash, cash equivalents and marketable securities $411.0M as of March 31, 2026
- Phase 3 EMPEROR enrollment of ~150 patients on track to complete June 2026; data readout mid-2027
- Raised $80.7M via ATM sales of 2.6M shares in Q1 2026
Financial Impact
Net loss per share of $0.79 slightly beat consensus of $0.80, but revenue miss is not comparable due to license timing. Cash runway extended into 2028.
Risk Factors
- Phase 3 EMPEROR data may fail to replicate Phase 1/2a efficacy
- Dilution risk from continued ATM sales ($80.7M raised in Q1 2026)
- Regulatory delays or additional data requests from FDA
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-212020 |
| Document: stok-20260507.htm | 0001193125-26-212020 |
| Document: 0001193125-26-212020-index-headers.html | 0001193125-26-212020 |
| Document: 0001193125-26-212020-index.html | 0001193125-26-212020 |
| Document: 0001193125-26-212020.txt | 0001193125-26-212020 |
| 8-K Data (Synthetic) | 0001193125-26-212020 |
Track record
18 reports on STOK
3 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +17.49% at T+60 after the Aug 3, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $27.02 Now $26.63 −1.44% settles Feb 12
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $26.12 Now $26.63 +1.95% settles Feb 12
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $26.07 Now $26.63 +2.15% settles Feb 3
- Oct 29, 202618d ago 8-K Neutral 5/10 Entry $26.29 Now $26.63 +1.29% settles Jan 28
- Oct 21, 202626d ago 144 Bearish 6/10 Entry $25.70 Now $26.63 −3.62% settles Jan 20
- Sep 30, 20266w ago SC 13G Neutral 4/10 Entry $26.01 Now $26.63 +2.38% settles Dec 28
- Sep 25, 20267w ago 8-K Neutral 2/10 Entry $25.50 Now $26.63 +4.43% settles Dec 22
- Aug 18, 202612w ago Insider Cluster Neutral 3/10 Entry $33.03 to $26.20 Now $26.63 −19.38% ▼ −20.68% −19.13% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers